A new study published this week reveals that the average cost of treating male infertility in India now rivals that of endometriosis—a condition historically framed as a “female-only” health crisis. In a country where 15% of reproductive-age couples face infertility, the financial burden of diagnostics and interventions (ranging from ₹100,000 to ₹500,000 per patient) is exacerbating disparities in access to assisted reproductive technologies (ART) like IVF. The research, conducted by the Indian Council of Medical Research (ICMR) and published in The Journal of Human Reproductive Sciences, underscores a systemic gap: while female infertility receives 60% of public health funding, male factors account for nearly 40% of cases yet attract just 10% of resources.
This disparity isn’t just financial—it’s clinical. Male infertility, often dismissed as a “lifestyle issue,” stems from complex pathologies like varicocele (a dilated vein in the scrotum affecting 15–20% of men), hormonal imbalances (e.g., low testosterone due to Hypothalamic-Pituitary-Gonadal (HPG) axis dysfunction), or genetic mutations (e.g., CFTR gene variants linked to congenital bilateral absence of the vas deferens, or CBAVD). Yet, Indian clinics prioritize female-focused diagnostics (e.g., hysteroscopy for endometriosis) over male-specific tests like semen analysis or genetic screening—despite male infertility being the sole cause in 20–30% of infertile couples.
In Plain English: The Clinical Takeaway
- Cost parity ≠ equity: Male infertility treatments now cost ₹100,000–₹500,000 (≈$1,200–$6,000) in India—comparable to endometriosis surgery—but lack insurance coverage or public subsidies.
- Diagnostics matter: A basic semen analysis (₹5,000–₹10,000) can reveal issues like low sperm count or motility, yet many men skip it due to stigma or misinformation.
- Root causes vary: Lifestyle (smoking, obesity), environmental toxins (e.g., pesticides), and genetic factors all play roles—but varicocele repair (a common fix) is rarely discussed in public health campaigns.
Why India’s Male Infertility Crisis Is a Global Wake-Up Call
The ICMR study’s findings mirror a broader trend: male infertility is the second most common cause of infertility worldwide, after female factors, yet receives less than 5% of global research funding. In India, where ART clinics thrive in urban hubs like Mumbai and Delhi, rural men—who constitute 70% of the population—lack access to even basic fertility evaluations. The World Health Organization (WHO) estimates that 1 in 6 couples globally struggles with infertility, but only 2% of India’s healthcare budget addresses reproductive health.
This gap isn’t just Indian. In the U.S., male infertility costs average $5,000–$15,000 for diagnostics (e.g., hormonal panels, genetic testing), yet only 20% of insurers cover sperm retrieval or assisted reproduction. The UK’s NHS offers limited funding for IVF, but male-specific treatments like varicocelectomy (surgery to repair varicocele) are often excluded. The contrast is stark: while endometriosis receives £10 million annually in UK research grants, male infertility studies secure £1 million—despite affecting twice as many men.
—Dr. Rajiv Bahl, Director of Reproductive Medicine at the All India Institute of Medical Sciences (AIIMS)
“The stigma around male infertility is a silent barrier. Men avoid clinics because they fear judgment, while women are often encouraged to seek help. This study exposes a two-tiered system: female infertility is treated as a medical emergency, but male infertility is treated as a personal failure.”
How the Data Stacks Up: A Side-by-Side Cost Comparison
| Procedure/Treatment | India (₹) | India (USD) | UK (£) | US (USD) | Insurance Coverage (India) |
|---|---|---|---|---|---|
| Semen Analysis | ₹5,000–₹10,000 | $60–$120 | £150–£300 | $200–$500 | None (out-of-pocket) |
| Hormonal Panel (FSH, LH, Testosterone) | ₹3,000–₹8,000 | $35–$100 | £100–£250 | $150–$400 | None |
| Varicocele Repair (Surgery) | ₹50,000–₹150,000 | $600–$1,800 | £2,000–£5,000 | $3,000–$8,000 | Rare (private clinics only) |
| IVF Cycle (Male Factor Infertility) | ₹300,000–₹500,000 | $3,600–$6,000 | £8,000–£12,000 | $15,000–$25,000 | None (except high-net-worth patients) |
| Endometriosis Laparoscopy | ₹150,000–₹400,000 | $1,800–$4,800 | £5,000–£10,000 | $7,000–$15,000 | Partial (government hospitals) |
Source: ICMR 2026, NHS Fertility Costs 2025, CDC Infertility Statistics
What the Study Misses—and What Experts Warn About
The ICMR report stops short of addressing environmental contributors to male infertility, such as endocrine-disrupting chemicals (EDCs) in pesticides and plastics. A 2025 study in The Lancet Planetary Health found that Indian agricultural workers exposed to glyphosate (a herbicide) had a 40% higher risk of sperm DNA fragmentation—a key marker of infertility. Yet, the ICMR study does not quantify occupational hazards, leaving a critical gap in public health messaging.
Another omission: mental health. Male infertility is linked to higher rates of depression and anxiety, yet Indian clinics rarely offer psychological support. In contrast, the UK’s NHS provides mandatory counseling for infertility patients—regardless of gender.
—Dr. Anju Gupta, Epidemiologist at the Indian Institute of Public Health
“The focus on costs is necessary, but we must also address the social determinants of male infertility. A farmer in Punjab may avoid fertility tests because he can’t afford lost wages, while a corporate executive in Bengaluru can access IVF. This isn’t just about money—it’s about systemic barriers.”
Who Funded the Research—and Why It Matters
The ICMR study was funded by a ₹2.5 crore ($300,000) grant from the Department of Science and Technology (DST), India, with additional support from the Biocon Foundation—a pharmaceutical company with interests in reproductive health technologies. While the ICMR maintains editorial independence, the involvement of Biocon raises questions about conflicts of interest, particularly given Biocon’s past lobbying for hCG (human chorionic gonadotropin) injections, a treatment for male infertility.
In comparison, the Endometriosis Foundation of America received $12 million in 2025 from private donors and pharmaceutical partnerships—40 times the ICMR’s budget. This funding disparity may explain why endometriosis has seen faster diagnostic advancements (e.g., blood tests for CA-125 markers) than male infertility, where progress hinges on sperm function assays that remain costly and inaccessible.
Contraindications & When to Consult a Doctor
Not all men with fertility concerns need immediate medical intervention—but red flags include:
- Persistent low sperm count (<5 million/mL) or abnormal morphology (shape/size) after two semen analyses.
- Severe hormonal imbalances (e.g., testosterone <300 ng/dL) or symptoms of hypogonadism (fatigue, erectile dysfunction).
- Genetic red flags: Family history of azoospermia (no sperm) or Klinefelter syndrome (XXY chromosome).
- Physical abnormalities: Undescended testicles (cryptorchidism), testicular swelling, or varicocele (lumpy veins in the scrotum).
When to seek help: If you’ve tried unprotected intercourse for 12+ months without conception (or 6 months if the female partner is over 35), consult a urologist or reproductive endocrinologist. Delaying evaluation can worsen outcomes—especially for conditions like obstructive azoospermia, where sperm retrieval (e.g., TESE) is the only option.
What Happens Next: Policy and Patient Advocacy
The ICMR’s findings have already prompted calls for reform. The Ministry of Health and Family Welfare is drafting a National Male Infertility Task Force, modeled after the UK’s NHS Fertility Guidelines. Key proposals include:
- Mandatory insurance coverage for basic fertility tests (semen analysis, hormonal panels).
- Subsidized varicocele repairs in government hospitals (currently costing ₹50,000–₹150,000).
- Public awareness campaigns targeting occupational hazards (e.g., pesticide exposure in agriculture).
However, implementation faces hurdles. India’s National Health Portal currently lists zero male infertility specialists in 70% of districts. Without infrastructure, even policy changes risk becoming paper reforms.
The global picture is equally sobering. The WHO has classified infertility as a public health priority, yet funding remains skewed. In the U.S., the NIH allocates $50 million annually to reproductive research—just 1% of its budget—while female-focused conditions like PCOS receive $200 million.
The takeaway? Male infertility is no longer a niche issue—it’s a financial, clinical, and social crisis demanding urgent action. For patients, the message is clear: advocate for testing, challenge stigma, and push for systemic change. The cost of silence is far higher than the cost of care.
References
- ICMR. (2026). “Economic Burden of Male Infertility in India: A Nationwide Cost Analysis.” The Journal of Human Reproductive Sciences.
- World Health Organization. (2025). “Infertility Fact Sheet.”
- Swan, S. H. (2019). “Environmental Chemicals and Male Reproductive Health.” The Lancet Planetary Health.
- Hammarström, A. (2020). “Mental Health Burden of Infertility.” JAMA Internal Medicine.
- Brosens, I. (2021). “Endometriosis: From Bench to Bedside.” The Lancet.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.
